pharmaceutical investing Oragenics Resumes Phase 2 Clinical Trial of AG013 in Oral Mucositis Following Positive Routine Safety Review
Ni-Co Energy Reports 4.60 Metres at 0.59% Nickel at Kremer-2; Phase-One Drilling Advances Magmatic Sulphide Exploration Model